Savara (NASDAQ:SVRA) Stock Rated Buy in New Coverage at HC Wainwright

Research analysts at HC Wainwright began coverage on shares of Savara (NASDAQ:SVRA) in a note issued to investors on Thursday, Benzinga reports. The firm set a “buy” rating and a $10.00 price target on the stock. HC Wainwright‘s target price suggests a potential upside of 100.40% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the company. Royal Bank Of Canada set a $10.00 target price on Savara in a report on Wednesday, October 7th. Citigroup reaffirmed a “market outperform” rating on shares of Savara in a research report on Wednesday, October 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Thursday, October 15th. JPMorgan Chase & Co. began coverage on shares of Savara in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price objective on the stock. Finally, Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.25.

Savara Trading Up 1.4%

Shares of SVRA stock opened at $4.99 on Thursday. Savara has a 1-year low of $4.03 and a 1-year high of $7.01. The company has a current ratio of 8.55, a quick ratio of 10.13 and a debt-to-equity ratio of 0.28. The stock’s fifty day simple moving average is $4.96 and its 200-day simple moving average is $5.35.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.01. On average, sell-side analysts expect that Savara will post -0.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Nan Fung Trinity HK Ltd. increased its position in Savara by 1,088.3% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company’s stock worth $9,507,000 after purchasing an additional 1,687,310 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Savara during the 3rd quarter valued at about $54,000. Profund Advisors LLC lifted its holdings in shares of Savara by 7.3% during the 3rd quarter. Profund Advisors LLC now owns 49,741 shares of the company’s stock valued at $257,000 after buying an additional 3,370 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Savara by 14.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 37,488 shares of the company’s stock valued at $190,000 after buying an additional 4,874 shares in the last quarter. Finally, Moody Aldrich Partners LLC grew its stake in shares of Savara by 4.2% in the 3rd quarter. Moody Aldrich Partners LLC now owns 502,932 shares of the company’s stock valued at $2,595,000 after buying an additional 20,139 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.